Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologyAetna actinic keratoses coverage update | OpenPaye…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0567

    Actinic Keratoses Treatments

    Customize your policy alerts

    Sign up for Aetna Policy 0567 alerts

    Get alerted when Policy 0567 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity, investigational status, and coding guidance for treatments of actinic keratoses for Aetna members; covers lesion-directed and field therapies and identifies interventions considered experimental/investigational.

    Policy Summary
    PayerAetna
    PolicyActinic Keratoses Treatments
    Policy CodePolicy 0567
    Change TypeNo material change
    Effective DateNov 9, 2001
    Last ReviewAug 10, 2023
    Next Review DateJun 13, 2024
    Key ActionCPT and HCPCS codes are covered only if selection/medical-necessity criteria in the policy are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    83RCTs summarized
    42.2%Ingenol mebutate face clearance
    78.2%BF-200 ALA PDT clearance
    23–61.1%AK prevalence range
    >=10Experimental items

    Coverage Criteria

    Medically Necessary Interventions

    Aetna considers the following procedures medically necessary for treatment of actinic keratoses:

    Primary lesion-directed or topical therapies: Destruction of actinic keratoses lesions using either cryosurgery with liquid nitrogen OR topical diclofenac, imiquimod, ingenol mebutate gel, or 5-fluorouracil (with or without tretinoin)
    Surgical removal when SCC suspected: Curettage or excision when squamous cell carcinoma is suspected AND submission of a specimen for histologic analysis is needed

    Specimen submission required as part of procedure

    Second-line destructive therapies: Destruction of actinic keratoses using chemical peel, dermabrasion, laser therapy, or photodynamic therapy for members who have failed to adequately respond to topical imiquimod or 5-FU, or to cryosurgeryfailure of topical imiquimod or 5-FU, or cryosurgery
    Policy Summary
    PayerAetna
    PolicyActinic Keratoses Treatments
    Policy CodePolicy 0567
    Change TypeNo material change
    Effective DateNov 9, 2001
    Last ReviewAug 10, 2023
    Next Review DateJun 13, 2024
    Key ActionCPT and HCPCS codes are covered only if selection/medical-necessity criteria in the policy are met.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and Operational NotesBackgroundDefinitionsRevision History

    These are reserved for inadequate response to first-line measures

    Experimental and Investigational

    Aetna considers the following interventions experimental and investigational for treatment of actinic keratoses because safety and effectiveness have not been established:

    Listed experimental therapies: Cream containing sunscreen, piroxicam and a retinoic/glycolic gel; intense pulsed light; lapatinib; microneedling; microwave therapy; non-ablative fractional thulium laser; thermal photodynamic therapy; topical calcipotriol; topical piroxicam; topical vitamin D and analogs

    Repetitive daylight PDT is also considered experimental/investigational for prevention of actinic keratoses

    Clinical coverage-related evidence and scenarios

    Evidence and guideline-aligned scenarios supported by the document:

    Ingenol mebutate efficacy: Ingenol mebutate gel applied for 2–3 days demonstrated significantly higher complete clearance versus placebo for face/scalp and trunk/extremities in randomized trialsface/scalp: 42.2% vs 3.7%; trunk/extremities: 34.1% vs 4.7%

    Local reactions peak early and resolve typically by day 29

    PDT efficacy: Photodynamic therapy with 5-ALA or MAL shows higher participant and lesion clearance versus placebo-PDT and, in some trials, superiority over alternative formulations (e.g., BF-200 ALA vs MAL)BF-200 ALA: patient clearance 78.2% vs 17.1% (trial); pooled ALA/MAL-PDT participants cleared per 1,000: 527–656 vs 89–147 for placebo

    Efficacy dependent on photosensitizer formulation and light source

    When PDT is clinically appropriate: PDT may be used for multiple or field AK lesions, superficial and confluent AKs, or when other therapies are less appropriate or have failedGuidelines suggest reserving PDT for extensive AKs not controlled with other therapies due to cost and inconvenience

    British and European guidelines referenced

    Surgical/destructive methods: Curettage, excision, shave removal, cryosurgery, chemical peels, dermabrasion, and laser resurfacing are acceptable lesion-directed options; curettage allows histologic submission when SCC suspectedIndicated for larger or suspicious lesions, immunocompromised patients, or when deeper removal is needed

    Scarring, anesthesia, and procedure-specific risks noted

    Evidence-informed coverage considerations

    Evidence summaries and comparative findings that could inform coverage decisions:

    Field-directed treatments vs vehicle/placebo: Randomized trials and meta-analyses show participant complete clearance significantly favored diclofenac/hyaluronic acid, 0.5% 5-FU, 5% imiquimod, and ingenol mebutate versus vehicle/placeboas reported in RCTs and Cochrane review

    Consider adverse-event profiles and withdrawals when comparing treatments

    Photodynamic therapy (PDT): PDT (ALA and MAL) shows significant benefit for lesion and participant clearance compared with placebo-PDT and may offer better cosmetic outcomes than cryotherapy; some trials favor ALA-PDT vs cryotherapyparticipant and lesion clearance measures per cited RCTs

    Evidence in organ transplant recipients suggests MAL-PDT is best-studied in that group

    Comparative ranking: Network meta-analysis ranked 5-FU highest, followed by ALA-PDT, imiquimod, ingenol mebutate, MAL-PDT, cryotherapy, diclofenac, then placebo; rankings should be interpreted with tolerability and other clinical considerationsbased on participant complete clearance in included trials

    See network meta-analysis results

    High-risk population (OTRs): In organ transplant recipients, limited RCT evidence suggests MAL-PDT has the highest participant complete clearance and field-directed regimens are preferable to lesion-directed approachesapplicability to immunosuppressed OTRs

    Evidence base is limited and risk of bias is high

    Evidence summaries (no explicit coverage decision stated)

    Evidence summaries and key findings

    Micro-needling + PDT: Combination microneedling plus PDT showed a small mean additional lesion clearance (~6% more lesions cleared vs PDT alone) in heterogeneous low-quality RCTs; standardization and higher-quality trials are needed

    UpToDate review does not mention MN+PDT

    Microwave therapy: A small internally controlled randomized trial (11 subjects, 179 AKs) reported higher response in treated areas (90% vs 15% controls) with severe but brief pain; larger RCTs against effective comparators are needed

    First-in-human feasibility data

    Repetitive daylight PDT for prevention: A randomized multicenter study (58 patients) found fewer new AKs after repetitive daylight PDT than cryosurgery but the difference was not statistically significant; daylight PDT improved photo-aging signs and had less pain

    Prevention efficacy not proven

    Adapalene pre-treatment before ALA-PDT: A small non-blinded study (15 patients) suggested 1-week adapalene pre-treatment before ALA-PDT increased lesion count reduction versus ALA-PDT alone and was well tolerated

    Small sample; hypothesis-generating

    Calcipotriol plus 5-FU: Systematic review found calcipotriol+5-FU reduced more AKs versus 5-FU+petroleum jelly and lowered cSCC risk over 3 years in limited trials, but direct comparisons to 5-FU monotherapy and other topicals are lacking

    More trials needed for comparative conclusions

    Topical treatment in organ transplant recipients (OTRs): A phase-II RCT (40 OTRs, 903 AKs) found 5-FU and imiquimod superior to sunscreen for AK clearance and prevention of new AKs; 5-FU appeared more effective than imiquimod in exploratory analyses though with greater toxicity

    Supports further phase-III chemoprevention trials

    Ameluz (10% ALA gel) with blue-light PDT: Randomized trial data support high lesion clearance with 10% ALA gel plus blue-light activation (GEL) and retrospective series suggest PDT tolerability for larger treatment areas (75–300 cm2) with appropriate post-PDT carelesion clearance rates as reported in trials

    Formulation and light source affect outcomes and local reactions

    The policy lists several technologies that are designated as experimental and investigational for treatment of actinic keratoses because safety and effectiveness have not been established. These include thermal photodynamic therapy, intense pulsed light (IPL), non-ablative fractional thulium laser, microneedling, microwave therapy, and other specified modalities. CPT/HCPCS coding guidance in the document flags these interventions as not covered for the CPB indications when they are listed as investigational (no specific procedure codes apply to those listed items).

    Photodynamic therapy using established topical photosensitizers (e.g., aminolevulinic acid 10% gel or 20% solution, methyl aminolevulinate) is described elsewhere in the policy as an accepted option in defined circumstances, but thermal PDT (distinct device/technique) is specifically singled out among investigational approaches.

    The document notes limited evidence that any AK treatment reduces progression to invasive squamous cell carcinoma (SCC). Systematic reviews and trials of photodynamic therapy and other interventions are limited by short follow-up durations and there are no conclusive data demonstrating long-term prevention of SCC, which constrains claims about durable chemoprevention.

    Because long-term outcomes (including reduction in subsequent invasive SCC) are not well established in the trials and reviews cited, the policy treats prevention of progression as an evidence gap rather than a demonstrated benefit.

    Topical vitamin D analogs and topical piroxicam are discussed as having insufficient or unsupported evidence for treatment of AK. A systematic review of off-label topical vitamin D analogs reported that topical vitamin D is ineffective for AK, and commentary on topical piroxicam notes that further controlled trials are needed and that major clinical reviews (UpToDate) do not list piroxicam as an established AK therapy.

    Accordingly, these agents are listed among interventions considered investigational or not supported by current evidence for AK indications in this policy.

    Some modalities have preliminary or early-phase evidence but remain insufficiently validated for routine coverage. Combination micro-needling plus PDT showed a small additional mean lesion clearance (~6% more lesions cleared versus PDT alone) in pooled, heterogeneous RCTs, but studies were low quality and protocols lacked standardization.

    Microwave therapy produced promising results in a small randomized internally controlled trial (179 AKs in 11 subjects) with higher response in treated areas versus controls, but the study’s small sample size, short follow-up, and feasibility design mean larger randomized trials against effective comparators are needed before it can be considered established.

    The policy explicitly identifies repetitive daylight photodynamic therapy as experimental and investigational for prevention of actinic keratoses because effectiveness for prevention has not been established. A cited randomized multicenter trial failed to show a statistically significant reduction in new AKs compared with cryosurgery, despite improvements in photo-aging measures and lower pain.

    Within the provided excerpts there are no statements framed as an explicit blanket "not medically necessary" determination separate from the experimental/investigational listings. The policy distinguishes interventions supported as medically necessary, those reserved after failure of first-line therapies, and a set of interventions characterized as experimental/investigational due to insufficient evidence.

    A systematic review of off-label uses concluded that topical vitamin D analogs are ineffective for actinic keratoses. The policy therefore lists topical vitamin D and analogs among interventions without supportive evidence and treats them as investigational for AK treatment.

    Coding

    Covered CPT Codes (if selection criteria met)CPTCovered
    11300Shaving of epidermal or dermal lesion, single lesion, trunk, arms or leg; lesion diameter 0.5 cm or less.
    11301Shaving of epidermal or dermal lesion, lesion diameter 0.6 to 1.0 cm.
    11302Shaving of epidermal or dermal lesion, lesion diameter 1.1 to 2.0 cm.
    11303Shaving of epidermal or dermal lesion, lesion diameter over 2.0 cm.
    11305Shaving of epidermal or dermal lesion, single lesion, scalp, neck, hands, feet, genitalia; lesion diameter 0.5 cm or less.
    11306Lesion diameter 0.6 to 1.0 cm.
    11307Lesion diameter 1.1 to 2.0 cm.
    11308Lesion diameter over 2.0 cm.
    11310Shaving of epidermal or dermal lesion, single lesion, face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 0.5 cm or less.
    11311Lesion diameter 0.6 to 1.0 cm.
    1–10 of 41
    1/5
    Photodynamic therapy CPT codesCPTCovered
    96567Photodynamic therapy by external application of light to destroy pre-malignant and/or malignant lesions of the skin and adjacent mucosa, each phototherapy exposure session.
    96573Photodynamic therapy with application and illumination/activation of photosensitizing drug(s) provided by a physician or other qualified health care professional, per day.
    HCPCS codes for topical photosensitizersHCPCSCovered
    J7308Aminolevulinic acid HCL for topical administration, 20%, single unit dosage form (354 mg).
    J7345Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg.
    J7309Methyl aminolevulinate (MAL) for topical administration, 16.8%, 1 gram [discontinued].
    ICD-10 CodesICD-10
    L57.0Actinic keratosis
    CPT/HCPCS codes not covered for listed indicationsmixedNot Covered
    Thermal PDT / IPL / non-ablative fractional thulium laser / microneedling / microwave therapy / repetitive daylight PDTNo specific CPT/HCPCS code - interventions listed as not covered for indications in this CPB.
    Referenced PDT products/devicesmixed
    Levulan Kerastick (20% ALA)FDA-approved drug/device combination for PDT (brand/product referenced).
    Ameluz (aminolevulinic acid gel, 10%)Approved in combination with BF-RhodoLED for lesion- and field-directed treatment of mild-to-moderate AKs of the face and scalp.
    Metvixia (methyl aminolevulinate cream, 16.8%)Previously marketed product (withdrawn from U.S. market as noted).
    No explicit billing or procedural codes in these chunksmixed
    No codes listed
    Number of lesions — CPT codes (lesion counts)
    CPT code — first lesion17000: Destruction, premalignant lesions; first lesion
    CPT code — 2 to 14 lesions17003: Second through 14 lesions, each
    CPT code — 15 or more lesions17004: 15 or more lesions

    Provider Actions and Operational Notes

    Prior Authorization

    Prior authorization / Coding and denial risk

    CPT and HCPCS codes for photodynamic therapy (PDT) and related products are payable only when the selection and medical‑necessity criteria in this policy are met. Codes for interventions listed as experimental/investigational in this policy may be denied.

    • Covered HCPCS: J7308 (ALA 20%), J7345 (ALA 10% gel) — only if policy criteria met.
    • Disallowed/Investigational techniques (no specific CPT/HCPCS codes): thermal PDT, repetitive daylight PDT, intense pulsed light, microwave therapy, microneedling, non-ablative fractional thulium laser.
    Note

    Prior authorization — administrative note

    This excerpt does not specify a formal payer prior authorization requirement for PDT or other AK treatments. Where prior authorization processes exist at the plan level, providers must follow the payer’s routine prior authorization workflows.

    • No explicit prior authorization rules listed in this policy excerpt.
    • Verify member benefits and any plan-level prior authorization requirements before treatment.
    Note

    Prior authorization — evidence‑informed guidance

    Evidence-informed guidance in the clinical background supports using PDT (ALA or MAL) as an option for patients with extensive or refractory AKs and for certain high‑risk populations (e.g., organ transplant recipients). The policy does not establish step‑therapy requirements but summarizes evidence that may inform clinical decision-making.

    • Guideline-style recommendations: PDT may be reserved for extensive AKs not controlled with cryotherapy or topical 5‑FU.
    • No formal step therapy mandated by this policy; evidence may favor 5‑FU or PDT ahead of less-studied modalities.
    Prior Authorization

    PDT (ALA) prior authorization and documentation considerations

    Specific clinical/operational considerations for topical ALA PDT (e.g., Ameluz 10% gel) should be documented when used, particularly for large‑area treatments. Documents should support the indication, treatment area, and expected post‑treatment care to help substantiate medical necessity.

    • Record treated surface area (noting studies reporting use up to 75–300 cm2).
    • Document product used (ALA 10% gel vs ALA 20% solution), light source (blue or red), incubation time, and post‑PDT care instructions.
    • Note if treatment is lesion‑directed or field‑directed and rationale (e.g., extensive or refractory AKs, organ transplant recipient).
    Denial Risk

    Denial risk — evidence limitations

    Evidence limitations for newer or less‑studied interventions (small trials, first‑in‑human studies, or techniques listed as investigational) may lead to claim denials or coverage exclusions. Providers should cite RCT data or guideline support when available.

    • Interventions considered investigational by this policy (may trigger denial): thermal photodynamic therapy, repetitive daylight PDT for prevention, microwave therapy (pending larger RCTs), microneedling, topical agents lacking evidence.
    • Provide trial identifiers, peer‑reviewed publications, and rationale when requesting coverage for less-established treatments.
    Note

    Provider responsibility — policy scope and benefit verification

    Clinical Policy Bulletins (CPBs) summarize clinical evidence and coverage positions but do not guarantee payment. Providers remain responsible for verifying member benefits, obtaining any required authorizations, and for treatment decisions.

    • CPB content is informational and may be updated; always confirm plan-specific coverage and benefit design.
    • Obtain prior authorization if required by the member’s plan and document medical necessity in the record.
    Documentation Required

    Specimen submission when carcinoma suspected

    When curettage or excision is performed because invasive squamous cell carcinoma (SCC) is suspected, submission of the specimen for histologic analysis is required and should be documented in the medical record.

    • Include pathology report or specimen submission documentation in the patient record when SCC is suspected.
    • Curettage/excision for suspected carcinoma is considered medically necessary when histologic analysis is indicated.
    Documentation Required

    No explicit documentation/authorization workflow provided

    This excerpt does not list explicit documentation or authorization steps beyond standard medical-record documentation and plan-level prior authorization processes. Clinical justification (lesion characteristics, prior therapies tried, and rationale for modality choice) should be included in requests.

    • Document prior treatments and responses (e.g., prior cryotherapy, topical 5‑FU or imiquimod) when seeking coverage for alternative modalities.
    • State lesion location, size, number, and whether lesion‑directed or field‑directed therapy is required.
    Documentation Required

    Evidence documentation expectations

    Summarize and cite relevant evidence when requesting coverage for treatments. The policy references systematic reviews, network meta-analyses, RCTs, and guideline statements as the basis for recommendations and coverage positions.

    • Preferred supporting evidence: RCTs, Cochrane or systematic reviews, guideline recommendations (e.g., British Association of Dermatologists, European Dermatology Forum).
    • Include lesion‑level and participant‑level outcome data when available (clearance rates, adverse events).
    Documentation Required

    Document treatment area and post‑PDT care

    For large-area PDT treatments, document the exact area treated and the post‑PDT care regimen provided and followed by the patient (e.g., zinc oxide, healing creams, sun protection) because adverse effects and mitigation strategies are relevant to medical necessity and safety.

    • If treating >20 cm2 (FDA‑largest approved field for some products), include rationale for larger field and documentation of patient counseling and post‑treatment instructions.
    • Note any deviations from manufacturer‑recommended incubation or illumination protocols with clinical justification.
    Step Therapy

    Treatment sequencing and guideline‑style recommendations

    Treatment sequencing considerations: cryosurgery, topical therapies (5‑FU, imiquimod, diclofenac, ingenol mebutate), and curettage/excision (when SCC suspected) are first‑line options. PDT is often considered for extensive or refractory AKs; no formal step‑therapy requirements are specified in this policy excerpt.

    • Consider 5‑FU or imiquimod for field therapy, especially in organ transplant recipients where RCT data support topical agents.
    • PDT may be preferred for superficial, confluent, or extensive lesions not controlled by standard therapies.
    Note

    Policy history and versioning

    Policy history and review dates are provided in the policy header; ensure requests reflect the current policy effective date and most recent review.

    • Policy Effective Date: 11/09/2001; Last Review: 08/10/2023; Next Review: 06/13/2024.
    • Use current policy version when preparing prior authorization or coverage justification.

    Background

    Actinic keratoses (AKs) are sun‑induced, premalignant epidermal lesions that present as circumscribed, rough, scaly patches on chronically sun‑exposed skin. They are common, increase in prevalence with age, male sex, immunosuppression and prior skin cancer history, and are managed using either lesion‑directed approaches (e.g., cryosurgery, curettage/excision) or field‑directed therapies (topical agents, photodynamic therapy, chemical peels, dermabrasion, laser) depending on lesion characteristics and clinical context.

    Because AKs have the potential to progress to squamous cell carcinoma (SCC) but long‑term data showing prevention of SCC are limited, clinical decision-making focuses on lesion characteristics (size, thickness, suspicion for invasive disease), symptom burden, patient risk factors (e.g., immunosuppression), and the expected benefits and risks of lesion‑directed versus field therapies.

    Definitions

    Actinic keratosis (AK) — definition and description
    DefinitionActinic keratosis (AK): sun-induced, pre-cancerous epidermal lesion presenting as circumscribed rough, scaly patches on sun-exposed skin that may progress to squamous cell carcinoma
    Typical locationsFace, head, neck, forearms, hands, upper back (actinic cheilitis is a variant on the lip)
    Risk factors/importanceMore common in fair-skinned individuals, increases with age, male sex, immunosuppression, and prior skin cancer history; prevalence reported 23–61.1%
    Cryosurgery with liquid nitrogen — definition and practice notes
    DefinitionCryosurgery with liquid nitrogen: lesion-directed destructive procedure applying liquid nitrogen to freeze and slough AK lesions
    Typical practice notesUsually used for discrete AKs; generally does not require local anesthetic and involves mild pain and transient post-procedural erythema
    When indicatedAppropriate for isolated, discrete lesions rather than extensive field disease
    Ingenol mebutate — definition and mechanism/usage notes
    DefinitionIngenol mebutate: topical field therapy applied for 2–3 days (0.015% for face/scalp; 0.05% for trunk/extremities) for treatment of AKs
    Mechanism and usageDual mechanism: rapid lesion necrosis plus neutrophil-mediated, antibody-dependent cellular cytotoxicity; short course therapy targets residual dysplastic cells after necrosis
    Efficacy noteRandomized trials showed higher complete clearance versus placebo (face/scalp 42.2% vs 3.7%; trunk/extremities 34.1% vs 4.7%) with local reactions peaking early and resolving by ~day 29
    Photodynamic therapy (PDT) — definition and components
    DefinitionPhotodynamic therapy (PDT): a two-step treatment using a topical photosensitizing agent applied to lesions and activation with a specific light source to destroy atypical cells
    ComponentsPhotosensitizer (e.g., 5-ALA, aminolevulinic acid; methyl aminolevulinate/MAL) plus light source (blue or red light; device examples: BLU-U, BF-RhodoLED)
    Practice notesPhotosensitizer applied and, after incubation (e.g., 14–18 hours for 5-ALA), lesion is illuminated; common side effects include erythema, stinging/burning, edema, scaling/crusting; treatment typically requires a multi-day protocol
    Curettage — definition and role
    DefinitionCurettage: destructive scraping technique using a curette to remove lesions, treating to a deeper dermal level than cryosurgery
    RoleIndicated for larger lesions and lesions in immunocompromised patients; allows submission of specimen for histologic analysis when invasive SCC is suspected
    Practical considerationsMay be combined with electrosurgery to control bleeding; requires local anesthesia and carries scarring risk
    Participant complete clearance — trial outcome definition
    DefinitionParticipant complete clearance: the trial primary outcome defined as complete clearance of all target AK lesions in a participant as reported in RCTs and meta-analyses
    Use in evidence synthesesUsed across RCTs and Cochrane reviews to compare efficacy of field-directed and lesion-directed therapies (e.g., reported for ingenol mebutate, PDT, 5-FU, imiquimod)
    Reporting implicationsEffect sizes and network rankings are based on participant complete clearance and inform comparative effectiveness conclusions
    Organ transplant recipients (OTRs) — definition and high-risk relevance
    DefinitionOrgan transplant recipients (OTRs): chronically immunosuppressed patients after organ transplantation who are at high risk for progression of AK to invasive squamous cell carcinoma
    Relevance to treatment selectionField-directed regimens (e.g., MAL-PDT, 5-FU, imiquimod, diclofenac) are preferred in OTRs; MAL-PDT is the best-studied intervention in RCTs for this group
    Evidence noteLimited RCT evidence in OTRs (8 RCTs, 242 OTRs) suggests higher participant complete clearance with MAL-PDT (40–76.4%) compared with other modalities
    Field-directed therapy — definition and examples
    DefinitionField-directed therapy: treatment applied to a photodamaged area to address multiple visible and subclinical AKs rather than single lesions
    ExamplesPhotodynamic therapy (PDT), topical field regimens such as 5‑fluorouracil (5‑FU), imiquimod, diclofenac/hyaluronic acid, and ingenol mebutate
    PurposeAims to treat both clinical and subclinical lesions across a field and may reduce development of new lesions; choice influenced by extent of photodamage and patient risk factors

    Revision History

    2001-11-09policy_effective

    Policy became effective.

    2023-08-10last_review

    Policy last reviewed.

    2024-06-13next_review_scheduledLatest

    Next policy review scheduled.